Ligand Pharmaceuticals (LGND) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ligand Pharmaceuticals (LGND)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

108.66

2.80 (2.65%)

At close: Jan 14, 2025, 3:59 PM

108.55

-0.10%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	50.47
Market Cap	2.05B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.49
PE Ratio (ttm)	43.64
Forward PE	n/a
Analyst	Buy

Ask	112
Volume	71,790
Avg. Volume (20D)	124,350
Open	106.55
Previous Close	105.86
Day's Range	105.15 - 108.70
52-Week Range	67.53 - 129.90
Beta	undefined

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease ca...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 18, 1992

Employees 58

Stock Exchange NASDAQ

Ticker Symbol LGND

Website https://www.ligand.com

Analyst Forecast

According to 6 analyst ratings, the average rating for LGND stock is "Buy." The 12-month stock price forecast is $141.5, which is an increase of 30.22% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Ligand Pharmaceuticals is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $39.03M, reflecting a 38.89% YoY growth and earnings per share of 1.19, making a -13.77% decrease YoY.

Why Price Moved

2 months ago · Source

+11.12%

Ligand Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

10 months ago · Source

+19.86%

Ligand Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued guidance.

News

2 days ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

1 month ago · seekingalpha.com

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinf...

2 months ago · seekingalpha.com

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis...

2 months ago · businesswire.com

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m....

2 months ago · businesswire.com

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial mar...